Psoriasis Completed Phase 2 Trials for Ruxolitinib (DB08877)

Also known as: PSORIASIS / Psoriasis unspecified / Psoriasis, unspecified

IndicationStatusPhase
DBCOND0013339 (Psoriasis)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00617994Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With PsoriasisTreatment